TB-500 is a synthetic fragment of thymosin beta-4 (T-beta-4), a 43-amino-acid protein that is one of the most abundant intracellular peptides in mammalian cells. While thymosin beta-4 was originally identified for its role in thymus gland development, its tissue repair properties have made it the subject of extensive research across musculoskeletal, cardiovascular, and neurological injury models. TB-500 reproduces the active region of the full thymosin beta-4 molecule responsible for actin sequestration and cell migration — the core mechanisms driving its healing effects.

This protocol covers the systemic application of TB-500 for multiple injury types, practical dosing structure, combination with BPC-157, and the monitoring approach for tracking recovery progress.

Mechanism overview

TB-500's healing effects are fundamentally different from BPC-157's, which is why the two are frequently combined. Understanding the mechanisms helps practitioners select the appropriate peptide — or combination — for each clinical scenario.

Actin regulation and cell migration: TB-500 binds to and sequesters G-actin (monomeric actin), preventing premature polymerization into F-actin (filamentous actin). This maintains a pool of available actin monomers and promotes the formation of dynamic, flexible actin structures at the cell leading edge. The practical result: cells can migrate more efficiently toward injury sites. This applies to endothelial cells (blood vessel formation), keratinocytes (wound closure), and stem/progenitor cells (tissue repair).

Neovascularization: TB-500 promotes the formation of new blood vessels in damaged tissue. While BPC-157 also has angiogenic properties (via VEGFR2 upregulation), TB-500 acts through a distinct pathway — promoting endothelial cell migration and tubule formation via the actin-regulation mechanism described above. This means the two peptides provide additive angiogenic effects rather than redundant ones.

Anti-inflammatory action: TB-500 modulates the inflammatory response without suppressing it entirely. It reduces inflammatory cytokine production while promoting the transition from the destructive inflammatory phase to the constructive proliferative phase of wound healing. This accelerates the healing timeline without compromising the initial immune response needed to clear debris and prevent infection.

Anti-fibrotic effects: Perhaps the most clinically significant differentiator. TB-500 reduces fibrotic scar formation in multiple tissue types. In cardiac tissue, this means less post-infarction fibrosis. In tendons and ligaments, it means more organized collagen deposition (functional tissue) versus disorganized scar tissue. This anti-fibrotic effect is a key advantage of TB-500 over interventions that simply accelerate healing without improving tissue quality.

Dose selection

Loading phase dose: 2-5 mg per injection, twice weekly for 2 weeks (4 total loading doses)

Maintenance dose: 2 mg per injection, once weekly

Aggressive loading (severe injury): 5 mg twice weekly for 2-3 weeks, then transition to 2 mg weekly maintenance

The loading phase rationale: TB-500 needs to establish systemic levels sufficient to saturate the actin-binding sites in injured tissue. The initial twice-weekly dosing builds tissue levels rapidly. The maintenance phase then sustains these levels at a lower input.

Unlike BPC-157, where proximity to the injury matters, TB-500 works systemically. The actin-regulation mechanism is not dependent on local concentration gradients — the peptide circulates and accumulates in areas of tissue damage and active cell migration.

Dose adjustment by injury severity

Injury severity	Loading dose	Loading frequency	Loading duration	Maintenance dose
Mild (minor strain, mild tendinopathy)	2 mg	Twice weekly	2 weeks	2 mg weekly
Moderate (partial tear, moderate tendinopathy, muscle injury)	4 mg	Twice weekly	2-3 weeks	2 mg weekly
Severe (complete tear recovery post-surgery, significant muscle damage, cardiac)	5 mg	Twice weekly	3 weeks	2-4 mg weekly

Route and administration

Route: Subcutaneous injection

Injection site: Abdominal subcutaneous tissue is the standard site. Unlike BPC-157, there is no meaningful advantage to injecting near the injury site — TB-500 distributes systemically regardless of injection location.

Needle gauge: 29-31 gauge, 0.5-inch insulin syringe

Volume: Depends on reconstitution concentration. A common approach: reconstitute a 5 mg vial with 1 mL bacteriostatic water, yielding 5 mg/mL. For a 2 mg dose, inject 0.4 mL. For a 5 mg dose, inject the full 1 mL.

Timing: No specific time-of-day preference. Some practitioners administer TB-500 on rest days rather than training days, reasoning that the healing processes benefit from a recovery state rather than an exercise-induced inflammatory state. This is logical but unproven in comparative studies.

Cycle structure

Standard healing cycle:

Loading phase: 2 weeks (4 doses)
Maintenance phase: 4-6 weeks
Total cycle: 6-8 weeks

Extended cycle (chronic conditions, post-surgical recovery):

Loading phase: 2-3 weeks
Maintenance phase: 8-10 weeks
Total cycle: 10-12 weeks

Rest period: 4-6 weeks between cycles if a subsequent cycle is planned. Unlike peptides that act on receptor systems (GH secretagogues, for example), TB-500 does not cause receptor desensitization. The rest period is primarily a practical and safety consideration — if the injury has healed, continued administration is unnecessary.

When to discontinue within a cycle: If the injury has functionally resolved (full range of motion, no pain, return to activity without limitations), the maintenance phase can be shortened. Completing the loading phase is important; cutting the maintenance phase short after confirmed healing is acceptable.

Injury-specific applications

Tendon injuries

Tendon injuries are the most common application for TB-500, and the preclinical evidence is strongest in this category.

Protocol adjustments for tendon:

Standard dosing applies (no tendon-specific dose modification)
Combine with BPC-157 for local injection near the affected tendon (see combination section)
Rehabilitation is critical — TB-500 improves tendon repair quality, but mechanical loading during healing (progressive tendon loading exercises) is necessary for proper collagen fiber alignment
Expected timeline: 2-3 weeks for pain reduction, 6-8 weeks for functional improvement, 3-6 months for full structural remodeling (the peptide cycle addresses the biological healing; the full structural timeline exceeds the cycle length)

Muscle injuries

Protocol adjustments for muscle:

Standard dosing applies
TB-500's anti-fibrotic effect is particularly valuable for muscle injuries, where scar tissue can significantly reduce contractile function
Begin TB-500 as soon as practical after acute muscle injury (post-initial 48-72 hour rest/ice phase)
Expected timeline: 1-2 weeks for pain reduction, 4-6 weeks for return to light activity, 8-12 weeks for full strength recovery

Cardiac applications

Thymosin beta-4 has been studied in cardiac injury models (myocardial infarction) with notable results: reduced infarct size, decreased cardiac fibrosis, and improved cardiac function in animal models. A Phase 1/2 clinical trial (RegeneRx Biopharmaceuticals) evaluated thymosin beta-4 in acute myocardial infarction patients and demonstrated safety with trends toward improved cardiac function.

Important context: Cardiac applications of TB-500 are the most evidence-rich area for thymosin beta-4 research but also the most medically serious. Self-administered TB-500 for cardiac injury is not recommended outside of medical supervision. This information is provided for educational context.

Protocol for medically supervised cardiac recovery:

Dose: 5 mg twice weekly during the acute post-event recovery phase (first 2-4 weeks)
Transition to 2-4 mg weekly for maintenance (8-12 weeks)
Monitoring: echocardiography at baseline, 4 weeks, and 8 weeks to assess ejection fraction and wall motion
Always in conjunction with standard-of-care cardiac rehabilitation and pharmacotherapy

Joint conditions (osteoarthritis, chronic joint inflammation)

Protocol adjustments for joints:

Standard dosing applies
Consider combining with pentosan polysulfate (PPS) for chondroprotective effects
TB-500 addresses the inflammatory and tissue repair components; PPS supports cartilage integrity and synovial fluid quality
Expected timeline: 3-4 weeks for inflammatory symptom improvement, 8-12 weeks for functional improvement. Structural cartilage changes, if any, require much longer assessment windows.

Combination with BPC-157

The TB-500 + BPC-157 combination is the most established peptide healing stack. The mechanistic rationale is strong: the two peptides address tissue repair through completely independent pathways.

TB-500 contribution: Systemic cell migration, neovascularization via actin regulation, anti-fibrotic effects, inflammatory phase transition

BPC-157 contribution: Local GH receptor upregulation, VEGFR2-mediated angiogenesis, nitric oxide modulation, local healing signal amplification

Combined protocol:

TB-500: Loading 2-5 mg twice weekly for 2 weeks; maintenance 2 mg weekly
BPC-157: 250-500 mcg daily, subcutaneous injection near the injury site
Duration: 6-8 weeks total for the combined stack

Injection strategy: TB-500 is injected in the abdomen (systemic delivery). BPC-157 is injected near the injury site (local delivery). This means two separate injection sites but leverages each peptide's strength — TB-500's systemic distribution and BPC-157's local signaling.

Timing within the day: Both can be injected at the same time. There is no pharmacological interaction between the two peptides. Using the same syringe is not recommended — draw and inject each peptide separately to ensure accurate dosing and avoid any compatibility concerns in the mixed solution.

Adding GHK-Cu to the stack

For injuries involving significant tissue remodeling (deep wounds, post-surgical recovery, severe tendon damage), GHK-Cu can be added as a third component.

GHK-Cu: 1-2 mg daily subcutaneous + topical application if a wound is present
Added benefit: extracellular matrix remodeling, collagen quality improvement, copper delivery for cross-linking enzymes
This three-peptide stack (TB-500 + BPC-157 + GHK-Cu) represents the most comprehensive peptide-based tissue repair approach currently available

Monitoring milestones

Week 1-2 (loading phase)

Reduction in acute inflammatory symptoms (swelling, warmth, redness)
Decreased pain at rest
These changes reflect the anti-inflammatory and vascular effects that are the earliest to manifest
Functional improvement is not expected during this phase

Week 3-4 (early maintenance)

Progressive pain reduction during activity
Improved range of motion
Sleep quality improvement (pain-related sleep disruption decreases)
Rehabilitation tolerance increases — the individual can perform more intensive physical therapy without flare-ups

Week 5-8 (late maintenance)

Measurable strength recovery
Return to modified activity or sport
Imaging improvement if tracked (ultrasound for tendon injuries: improved fiber organization, reduced hypoechoic areas; MRI for muscle: reduced edema signal, improved muscle architecture)
Functional milestones specific to the injury type

Post-cycle (weeks 9-12)

Continued healing trajectory — the biological processes initiated during the cycle continue after the peptide is discontinued
Rehabilitation program should be advancing to performance-level loading
If healing has plateaued or regressed, consider a second cycle after a 4-6 week rest period

Safety considerations

Tolerability: TB-500 is generally well-tolerated at standard doses. The most commonly reported adverse effects are:

Injection site reactions: mild redness, occasional bruising (standard for subcutaneous injection)
Temporary lethargy or fatigue: reported by some individuals during the loading phase, typically resolving within 24-48 hours of each dose
Head rush or lightheadedness: occasionally reported immediately after injection, brief and self-resolving

Theoretical concerns:

Cancer risk: Thymosin beta-4 promotes cell migration and angiogenesis — processes that are also important for tumor growth and metastasis. In preclinical studies, the evidence is mixed: some models show thymosin beta-4 promoting tumor growth, while others show neutral or even suppressive effects depending on the cancer type and context. The clinical significance for short-term TB-500 use (6-8 week cycles) in individuals without active malignancy is uncertain, but the theoretical concern warrants disclosure.

Recommendation: Individuals with active cancer, a history of cancer within the past 5 years, or known premalignant conditions should not use TB-500. Age-appropriate cancer screening should be current before initiating any peptide protocol with pro-angiogenic properties.

Drug interactions: No significant pharmacological interactions have been identified. TB-500 does not interact with common anti-inflammatory medications (NSAIDs), antibiotics, or standard rehabilitation medications. The use of NSAIDs alongside TB-500 is a common question — while NSAIDs can suppress the inflammatory response that healing depends on, short-term NSAID use for severe pain management is unlikely to negate TB-500's effects. Chronic high-dose NSAID use during a healing protocol is generally discouraged regardless of peptide use.

Pregnancy and breastfeeding: No safety data exists for TB-500 use during pregnancy or lactation. Avoid use in these populations.

Post-surgical use: TB-500 should not be initiated until hemostasis is confirmed post-surgery (typically 48-72 hours). The pro-angiogenic effects could theoretically interfere with initial surgical hemostasis. Begin after the acute post-surgical phase, with surgeon awareness.

Reconstitution and storage

Reconstitution: Add bacteriostatic water slowly to the lyophilized vial. Do not shake — gently swirl. Standard reconstitution: 1-2 mL bacteriostatic water per 5 mg vial.

Storage: Lyophilized peptide: room temperature or refrigerated. Reconstituted peptide: refrigerate at 2-8 degrees Celsius. Use within 3-4 weeks of reconstitution. Do not freeze reconstituted peptide.

Protocol summary

Parameter	Loading phase	Maintenance phase
Dose	2-5 mg	2 mg
Frequency	Twice weekly	Once weekly
Duration	2-3 weeks	4-8 weeks
Route	Subcutaneous (abdomen)	Subcutaneous (abdomen)
Primary combination	BPC-157 (250-500 mcg daily, near injury)	BPC-157 (same)
Key monitoring	Pain levels, inflammatory markers	ROM, strength, imaging
Cycle total	6-8 weeks (standard); 10-12 weeks (extended)
Rest between cycles	4-6 weeks